IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc.

Overview
Headquarters

7000 Shoreline Court, Suite 350, South San Francisco, CA, 94080, USA

Type of Company

Public

Employees (Worldwide)

62

Industries

Pharmaceuticals
Biotechnology
Wholesale: Consumer Non-Durables/Sundries
Hospitals & Patient Services
Computer Software

Company Description

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Executives & Employees

Co-Founder & Chief Executive Officer

Chief Financial Officer & Executive Vice President

Senior Vice President & General Counsel

Senior Vice President & Head of Biology & Translational Sciences

Vice President & Head-Drug Discovery

Vice President, Human Resources

Vice President, Development Operations

Vice President, Finance

Research Fellow

Board Observers

Board of Directors

General Partner at Canaan Management, Inc.

Chairman & Chief Executive Officer at Arcus Biosciences, Inc.

Former Chief Marketing Officer & Executive Vice President at Merck & Co., Inc.

Co-Founder & Chief Executive Officer at IDEAYA Biosciences, Inc.

President & Chief Executive Officer at Cidara Therapeutics, Inc.

Partner at Corvus Pharmaceuticals, Inc.

President-Clinical Sequencing & Oncology at Thermo Fisher Scientific, Inc.

Former Chief Medical Officer at The Multiple Myeloma Research Foundation, Inc.

Paths to IDEAYA Biosciences, Inc.
Potential Connections via
Relationship Science
You
IDEAYA Biosciences, Inc.
Owners & Shareholders
Details Hidden

BVF Partners pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The firm's investments within the biotechnology sector focus primarily on the securities of companies with market capitalizations of less than $1 billion. BVF may also invest in unregistered securities of public and closely-held private biotechnology companies by directly purchasing from issuers or other shareholders, in privately negotiated transactions, common stock, convertible preferred stock and/or debt instruments with warrants, options and/or similar rights to acquire an equity interest. The firm also pursues a second investment strategy on that invests in equity or equity-linked securities of companies involved in the biotechnology industry and related fields that, as of the time of the acquisition of such securities, have a market capitalization of $350 million to $3 billion.

Details Hidden

Canaan Management focuses on investments primarily in the technology and healthcare sectors. In the technology sector, the firm focuses on consumer, fintech, enterprise/cloud, and frontier tech. Within the healthcare sector, Canaan Partners focuses on investments in biopharmaceuticals, medical technology and digital health. The firm provides financing for early stage capital requirements.

Details Hidden

RTW Investments aims to generate attractive risk-adjusted returns through investments in securities, both equity and debt, long and short, of companies with a focus on the healthcare sector. The Funds will primarily invest in the equity and debt of public and private issuers globally, with a focus on the US and Europe. Derivatives are employed to improve payoff structures, as well as to construct hedges. The firm’s research process will be focused on a scientific approach to assessing and accurately defining the fundamental value of outcomes surrounding transformational events in the lifecycle of healthcare companies.

Recent Transactions
Details Hidden

IDEAYA Biosciences, Inc. issued USD Common Stock

Details Hidden

IDEAYA Biosciences, Inc. issued USD Common Stock

Details Hidden

IDEAYA Biosciences, Inc. raised money in a private placement transaction

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onIDEAYA Biosciences, Inc. issued USD Common Stock

Underwriter

Advised onIDEAYA Biosciences, Inc. issued USD Common Stock

Underwriter

Advised onIDEAYA Biosciences, Inc. issued USD Common Stock

Associate

Advised onIDEAYA Biosciences, Inc. issued USD Common Stock

Underwriter

Advised onIDEAYA Biosciences, Inc. issued USD Common Stock

Managing Director

Advised onIDEAYA Biosciences, Inc. issued USD Common Stock

Advisors & Consultants
Consultant

Interim Chief Executive Officer at Arch Oncology, Inc.

Key Stats and Financials As of 2020
Market Capitalization
$702M
Total Enterprise Value
$69.2M
Earnings Per Share
$-1.4
Enterprise Value / Sales
3.54x
EBITDAMargin
-173.83%
Debt TEV
0.1x
TEVNet Income
-2.01x
Net Profit
$-34.5M
Total Equity
$198M
Total Debt
$6.72M
EBITDA
$-34M
Revenue
$19.5M
Investors
Details Hidden

Canaan Management focuses on investments primarily in the technology and healthcare sectors. In the technology sector, the firm focuses on consumer, fintech, enterprise/cloud, and frontier tech. Within the healthcare sector, Canaan Partners focuses on investments in biopharmaceuticals, medical technology and digital health. The firm provides financing for early stage capital requirements.

Details Hidden

6 Dimensions Capital invests in early and growth stage companies in China, the U.S. and globally. The firm focuses on sectors such as biologics, small molecules, medical devices, diagnostics, medical services and healthcare IT.

Details Hidden

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

Suppliers
Icon Plc Biotechnology | Dublin, Ireland

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the strategic development, management and analysis of programs that support clinical development. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.

Novartis AG Medical Support Services | Basel, Switzerland

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

WuXi AppTec Co., Ltd. Pharmaceuticals | Shanghai, China

WuXi AppTec Co., Ltd. provides an integrated pharmaceutical platform for the research, development, and production of new drugs. It operates through the following business segments: Contract research organization (CRO) services, Contract manufacturing organization (CMO)/Contract development and manufacturing organization (CDMO) business, and Others. The CRO services segment includes laboratory services in China, laboratory services in the United States, and clinical research services. The company was founded by Ge Li, Ning Zhao, Xiao Zhong Liu, Zhao Hui Zhang, and Tao Lin on December 1, 2000 and is headquartered in Shanghai, China.

Competitors
Agios Pharmaceuticals, Inc. Pharmaceuticals - Cambridge, Massachusetts

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

GlaxoSmithKline Plc Pharmaceuticals - Brentford, Gbr

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by IDEAYA Biosciences, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of IDEAYA Biosciences, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and IDEAYA Biosciences, Inc..